Home › Macular Degeneration › Texas › Abilene
Macular Degeneration clinical trials in Abilene, TX
4 studies for Macular Degeneration are looking for participants at sites in and around Abilene (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
RecruitingPhase 2/3
- Retina Research Institute of Texas (Site 010), Abilene
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RecruitingPhase 1/2
- Retina Research Institute of Texas, Abilene
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RecruitingPhase 3
- Retina Research Institute of Texas, Abilene
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RecruitingPhase 1/2
- Retina Research Institute of Texas /ID# 262141, Abilene
About Macular Degeneration
Macular degeneration, or age-related macular degeneration (AMD), causes vision loss in older adults. Learn about the types and what can help.
More about Macular Degeneration on MedlinePlus
Macular Degeneration trials in other cities
- Dallas, TX13 studies
- Erie, PA10 studies
- The Woodlands, TX9 studies
- Sacramento, CA8 studies
- Hagerstown, MD8 studies
- Reno, NV8 studies
- Phoenix, AZ7 studies
- Cleveland, OH7 studies
- Houston, TX7 studies
- Salt Lake City, UT7 studies
- Boston, MA7 studies
- Austin, TX7 studies
Other studies in Abilene
- Non-Small Cell Lung Cancer8 studies
- Breast Cancer5 studies
- Metastatic Cancer5 studies
- Colorectal Cancer5 studies
- Ovarian Cancer4 studies
- Triple-Negative Breast Cancer3 studies
- Geographic Atrophy3 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.